Vaxil Bio is a biotechnology company focused on immuno-oncology as cancer treatments. It utilizes a proprietary platform for identification, isolation, and production of antigen-specific immunotherapies. Vaxil's lead product, ImMucin, is designed for the treatment of multiple myeloma. Additionally, the company develops signal peptide-specific antibodies and anti-infectives.